Skip to content

To evaluate the effect of CYP3A gene polymorphism on sufentanil dosage and postoperative analgesia in patients undergoing lumbar surgery based on IoC2

To evaluate the effect of CYP3A gene polymorphism on sufentanil dosage and postoperative analgesia in patients undergoing lumbar surgery based on IoC2

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000037613
Enrollment
Unknown
Registered
2020-08-29
Start date
2020-10-08
Completion date
Unknown
Last updated
2020-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

narcotic analgesic

Interventions

grouped according to whether they carried CYP3A4 * 1 and CYP3A5 * 3:Nil

Sponsors

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients undergoing elective general anesthesia downlink lumbar surgery, the han nationality, aged 18 to 65 years old, ASA I ~ III level, body mass index (BMI) of 18 to 25, line need PCA postoperative analgesia.

Exclusion criteria

Exclusion criteria: Severe systemic diseases such as heart, brain, liver and kidney; A history of mental and neurological diseases was determined before operation.A long history of smoking and alcohol abuse; A history of long-term use of valium or opioids;Liver CYP3A inducer or inhibitor was taken within 1 month before surgery.

Design outcomes

Primary

MeasureTime frame
The total amount of sufentanil used intraoperatively;The total amount of sufentanil used in the first 24 h controlled analgesia pump in each group after surgery;Mean visual analogue scale within 24h after surgery;

Secondary

MeasureTime frame
Occurrence of postoperative analgesia adverse reactions;

Countries

China

Contacts

Public ContactDing Lingling

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

dinglingling301@126.com+86 10-52176647

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026